Pamela Harriet Russell

Suggest Changes
Learn More
PURPOSE To ascertain the predictive value of Her-2/neu overexpression and p53 mutations, assessed by immunohistochemistry, in high-risk primary breast cancer (HRPBC) treated with high-dose(More)